Insider · CIK 0001361115
Dennis E Marshall
Files at BLGO (BIOLARGO, INC.). First filing -, latest -.
In brief
Dennis E Marshall files SEC Form 4 as director at BLGO (BIOLARGO, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Dennis E Marshall has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 18 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +281,248 | - | - | 6,056,317 | 11 d ago |
| Sep 30, 2026 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +234,375 | - | - | 6,290,692 | 11 d ago |
| Jun 30, 2026 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +198,238 | - | - | 5,639,476 | Jul 2, 2026 |
| Jun 30, 2026 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +115,741 | - | - | 5,804,674 | Jul 2, 2026 |
| Jun 22, 2026 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +40,909 | - | - | 5,463,738 | Jun 24, 2026 |
| Mar 31, 2026 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +138,889 | - | - | 5,317,088 | Apr 1, 2026 |
| Mar 31, 2026 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +115,741 | - | - | 5,432,829 | Apr 1, 2026 |
| Dec 31, 2025 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +122,084 | - | - | 5,144,645 | Jan 5, 2026 |
| Dec 31, 2025 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +101,736 | - | - | 5,246,381 | Jan 5, 2026 |
| Sep 30, 2025 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +132,351 | - | - | 4,957,267 | Oct 2, 2025 |
| Sep 30, 2025 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +110,294 | - | - | 5,067,561 | Oct 2, 2025 |
| Jun 30, 2025 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +19,000 | - | - | 4,717,566 | Jul 2, 2025 |
| Jun 30, 2025 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +112,501 | - | - | 4,765,781 | Jul 2, 2025 |
| Jun 30, 2025 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +93,750 | - | - | 4,859,531 | Jul 2, 2025 |
| Dec 31, 2024 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +98,684 | - | - | 4,624,625 | Jan 3, 2025 |
| Dec 26, 2024 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +118,422 | $0.00 | $0 | 4,525,941 | Dec 30, 2024 |
| Dec 31, 2023 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +111,607 | - | - | 4,108,116 | Jan 3, 2024 |
| Dec 31, 2023 | BLGO BIOLARGO, INC. | AGrant or award Option to Purchase Common Stockderivative | +133,929 | - | - | 4,152,045 | Jan 3, 2024 |
Questions about Dennis E Marshall
Answered from the filings on this page, as of the latest one.
Is Dennis E Marshall buying or selling?
Dennis E Marshall has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Dennis E Marshall's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Dennis E Marshall has 0.
Where does Dennis E Marshall file Form 4?
Dennis E Marshall has filed Form 4 at BLGO (BIOLARGO, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.